Health - The Post Chronicle (Free subscription) | 12/13/2008
U.S. health regulators are questioning whether clinical trials proposed by ImClone Systems and Amgen Inc will be adequate to show that patients with a certain type of gene are more likely to be helped by two cancer drugs, according to documents released on Friday....
euronews24 (Free subscription) | 12/12/2008
WASHINGTON Reuters U.S. health regulators are questioning whether clinical trials proposed by ImClone Systems and Amgen Inc will be adequate to show that patients with a certain type of gene are more likely to be helped by two cancer drugs, accord
Reuters UK (Free subscription) | 12/12/2008
WASHINGTON (Reuters) - U.S. health regulators are questioning whether clinical trials proposed by ImClone Systems and Amgen Inc will be adequate to show that patients with a certain type of gene are more likely to be helped by two cancer drugs, according to documents released on Friday.
DoughStreet.com (Free subscription) | 12/11/2008
Hello, ImClone. Goodbye profits. Eli Lilly will be in the red for 2008 thanks to more than billion in fourth-quarter charges related to the drugmaker’s .5 billion deal for ImClone Systems. For this year, the company said it now expects to record a loss of .56 to .06 a share, reflecting Imclone-related charges of .05 [...]
Business Wire (Free subscription) | 12/11/2008
CINCINNATI--(BUSINESS WIRE)--Eli Lilly & Co. (NYSE: LLY) stepped into the spotlight on Thursday when it predicted earnings growth of as much 15% next year, excluding costs from its ImClone Systems acquisition. This
Fiercebiotech (Free subscription) | 12/11/2008
As Eli Lilly outlined an annual loss for the company due to its acquisition of ImClone Systems , company officials also pointed to major progress in cutting R&D costs. Lilly officials say they are halfway to meeting their goal of cutting the cost of getting a new drug to market from the $1.2 billion average it recorded in 2007 to $800 million in 2010. As the ImClone acquisition made clear, Lilly sees...
Pharmalot (Free subscription) | 12/11/2008
In its annual briefing for Wall Streeters, the drugmaker offers sobering forecasts for next year and, meanwhile, will post a loss this year thanks to more than $4 billion in charges stemming from its $6.5 billion deal to buy ImClone Systems. “The pharmaceutical industry,” Lilly ceo John Lechleiter reminds the crowd,” continues to face major [...]
InformedTrades (Free subscription) | 12/11/2008
Eli Lilly & Co.'s costs associated with the acquisition of ImClone Systems will result in a 2008 net loss, wiping out the pharmaceutical giantâs...
Market Watch (Free subscription) | 12/11/2008
Eli Lilly & Co.'s costs associated with the acquisition of ImClone Systems will result in a 2008 net loss, wiping out the pharmaceutical giant’s earlier forecast for a full-year profit.
njbiz.com Daily (Free subscription) | 12/09/2008
Drug development company ImClone Systems has eliminated 50 of its 1,280 employees month after pharmaceutical company Eli Lilly completed its $6.5 billion purchase of ImClone.
Pharmalot (Free subscription) | 12/08/2008
The ink is barely dry on the acquisition papers, and already Lilly has directed its ImClone Systems unit to eliminate almost half of its sales reps. Lilly, you may recall, agreed two months ago to pay $6.5 billion for ImClone, which markets the Erbitux cancer med and figured in the Martha Stewart insider trading scandal, [...]
Business Wire (Free subscription) | 12/08/2008
NEW YORK--(BUSINESS WIRE)--ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY), and Bristol-Myers Squibb Company (NYSE: BMY) today announced that they have submitted an application to the
Medical News Today (Free subscription) | 11/25/2008
NCCN (The National Comprehensive Cancer Network) has been awarded a $1.5 Million grant from Bristol-Myers Squibb Company and ImClone Systems Incorporated to fund research on the antibody cetuximab in patients with bladder cancer. The novel targeted therapy has proven effective in various other types of cancer including colorectal and head and neck. The University of Michigan Comprehensive Cancer Center...
Indy Star (Free subscription) | 11/25/2008
INDIANAPOLIS Eli Lilly and Co. said Monday it has completed its $6 billion acquisition of ImClone Systems, the biggest buyout in the drug maker's 132-year history. In response, Fitch's Rating Service downgraded Lilly's issuer default rating from A-plus to AA, citing the debt Lilly needs for the acquisition. On Friday, when Lilly bought about 85.
Market Watch (Free subscription) | 11/24/2008
SAN FRANCISCO (MarketWatch) -- Fitch Ratings on Monday lowered Eli Lilly and Co.'s issuer default rating to A+ from AA and its short-term IDR to F1 from F1+. The downgrade is due to the the incremental debt needed to complete $6.5-billion buyout of ImClone Systems . "Fitch believes that the increased leverage heightens the sensitivity of Eli Lilly's credit profile while the company encounters its...
